Created at	Source	Raw Value	Validated value
Nov. 5, 2021, 2:05 p.m.	oms	participants were adults aged more than 18 years who completed 2 doses of a three-week schedule of Verocell, and have not had SARS-CoV-2 infection.	participants were adults aged more than 18 years who completed 2 doses of a three-week schedule of Verocell, and have not had SARS-CoV-2 infection.